Align Technology Inc (ALGN)
Align Technology, Inc. provides Invisalign clear aligners, Vivera retainers, and iTero intraoral scanners and services in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers Invisalign comprehensive package to treat adults and teens malocclusion and features, and orthodontic needs of teenage or younger patients; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients between the ages of six and ten years with a mixture of primary/baby and permanent teeth. This segment also provides Invisalign express, Invisalign lite, and Invisalign moderate; Invisalign Go, Invisalign Go express, and Invisalign Go Plus; retention products, Invisalign training, adjusting tools used by dental professionals during treatment, ancillary Invisalign accessory products, and other oral health products; Invisalign Professional Whitening system; Invisalign Palatal Expander, a 3D printed orthodontic device; and 3D printing solutions. Its Imaging Systems and CAD/CAM Services segment offers iTero intraoral scanning system, a single hardware platform for restorative or orthodontic procedures; exocad, a computer-aided design and computer-aided manufacturing software; orthodontist software for digital records storage, orthodontic diagnosis, and fabrication of printed models and retainers; and restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons. This segment also offers Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; Align Oral Health Suite, a digital interface for dental consultations; iTero TimeLapse technology for doctors or practitioners to compare a patient's historic 3D scans to the present-day scan; and subscription software, disposables, rents scanners, and pay per scan services. Align Technology, Inc. was incorporated in 1997 and is headquartered in Tempe, Arizona.
- Symbol
- ALGN
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Market cap
- $10.24B
- 52 week range
- 124.91 - 200.44
Valuation
- Share price
- $143.74 (close of 2026-10-02)
- P/E (TTM)
- 24.95x
- Price to book
- 2.42x
- Price to free cash flow
- 16.16x
- Enterprise value
- $9.26B
- Book value per share
- $59.41
Price performance
| Period | Change |
|---|---|
| 1 day | -1.11% |
| 5 days | -2.07% |
| 1 month | -9.68% |
| 3 months | -22.10% |
| 6 months | -15.74% |
| Year to date | -7.95% |
| 1 year | +11.69% |
| 3 years | -52.05% |
| 5 years | -78.29% |
| 10 years | +53.32% |
| All time | +751.54% |
Members of Congress who disclosed ALGN trades
Lisa McClain · Robert Bresnahan · Gilbert Ray Cisneros
Super investors holding ALGN
Ruane Cunniff (Ruane, Cunniff & Goldfarb L.P.) · Ken Griffin (Citadel) · Ray Dalio (Bridgewater Associates)
Profitability and growth
- Return on equity
- 10.13%
- Return on invested capital
- 12.08%
- Return on assets
- 6.58%
- Return on capital employed
- 12.65%
- Gross margin
- 67.19%
- Net margin
- 10.17%
- EBITDA margin
- 19.41%
- Revenue growth
- 0.90%
- Net income growth
- -2.61%
- Free cash flow growth
- -21.18%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 6.19%
- Current ratio
- 1.40x
- Net debt to EBITDA
- -1.08x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $4.03B
- Cost of revenue
- $1.32B
- Gross profit
- $2.71B
- EBITDA
- $783.19M
- Net income
- $410.35M
- Earnings per share
- $5.66
- Research and development
- $369.91M
- Shares outstanding
- 72.54M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|---|---|---|---|
| 2025-12-31 | $4.03B | $2.71B | $410.35M | $5.66 |
| 2024-12-31 | $4.00B | $2.80B | $421.36M | $5.63 |
| 2023-12-31 | $3.86B | $2.71B | $445.05M | $5.82 |
| 2022-12-31 | $3.73B | $2.63B | $361.57M | $4.62 |
| 2021-12-31 | $3.95B | $2.94B | $772.02M | $9.78 |
| 2020-12-31 | $2.47B | $1.76B | $1.78B | $22.55 |
| 2019-12-31 | $2.41B | $1.74B | $442.78M | $5.57 |
| 2018-12-31 | $1.97B | $1.45B | $400.24M | $5.00 |
| 2017-12-31 | $1.47B | $1.12B | $231.42M | $2.89 |
| 2016-12-31 | $1.08B | $815.29M | $189.68M | $2.38 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|---|---|---|---|
| 2025-12-31 | 67.19% | 10.17% | 10.13% | 12.08% |
| 2024-12-31 | 70.00% | 10.54% | 10.94% | 14.35% |
| 2023-12-31 | 70.08% | 11.52% | 12.26% | 15.86% |
| 2022-12-31 | 70.52% | 9.68% | 10.04% | 14.54% |
| 2021-12-31 | 74.26% | 19.53% | 21.31% | 27.79% |
| 2020-12-31 | 71.33% | 71.84% | 54.92% | 16.41% |
| 2019-12-31 | 72.46% | 18.40% | 32.89% | 50.31% |
| 2018-12-31 | 73.63% | 20.35% | 31.94% | 66.37% |
| 2017-12-31 | 75.81% | 15.71% | 20.05% | 31.70% |
| 2016-12-31 | 75.50% | 17.57% | 18.98% | 32.41% |
Cash and debt by year
| Period end | Cash |
|---|---|
| 2025-12-31 | $1.09B |
| 2024-12-31 | $1.04B |
| 2023-12-31 | $937.44M |
| 2022-12-31 | $942.05M |
| 2021-12-31 | $1.10B |
| 2020-12-31 | $960.84M |
| 2019-12-31 | $550.42M |
| 2018-12-31 | $636.90M |
| 2017-12-31 | $449.51M |
| 2016-12-31 | $389.27M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|---|---|
| 2025-12-31 | $490.78M | $185.87M |
| 2024-12-31 | $622.65M | $173.70M |
| 2023-12-31 | $608.06M | $154.03M |
| 2022-12-31 | $276.83M | $133.37M |
| 2021-12-31 | $771.45M | $114.34M |
| 2020-12-31 | $507.26M | $98.43M |
| 2019-12-31 | $597.56M | $88.18M |
| 2018-12-31 | $331.37M | $70.76M |
| 2017-12-31 | $242.84M | $58.85M |
| 2016-12-31 | $177.08M | $54.15M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-10-28
- Consensus EPS estimate
- $2.34
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-07-29 | Jun/2026 | $2.08 |
| 2026-04-29 | Mar/2026 | $1.74 |
| 2026-02-04 | Dec/2025 | $2.48 |
| 2025-10-29 | Sep/2025 | $1.88 |
| 2025-07-30 | Jun/2025 | $2.11 |
| 2025-04-30 | Mar/2025 | $1.51 |
| 2025-02-05 | Dec/2024 | $1.98 |
| 2025-01-29 | - | - |
Filings and sources
- Company website
- aligntech.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Teleflex Inc (TFX) · Avantor, Inc. (AVTR) · Cooper Companies, Inc. (COO) · Repligen Corp (RGEN) · Baxter International Inc (BAX) · Solventum Corp (SOLV) · West Pharmaceutical Services Inc (WST) · Medline Inc. (MDLN)
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades